The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Studies on gene therapy for hemophilia B (HB) using adeno-associated viral (AAV) vectors showed that the safety of a given strategy is directly related to the vector dose. To overcome this limitation, we sought to test the efficacy and the risk of immunogenicity of a novel factor IX (FIX) R338L associated with ∼ 8-fold increased specific activity. Muscle-directed expression of canine FIX-R338L by AAV vectors was carried out in HB dogs. Therapeutic levels of circulating canine FIX activity (3.5%-8%) showed 8- to 9-fold increased specific activity, similar to humans with FIX-R338L. Phenotypic improvement was documented by the lack of bleeding episodes for a cumulative 5-year observation. No antibody formation and T-cell responses to FIX-R338L were observed, even on challenges with FIX wild-type protein. Moreover, no adverse vascular thrombotic complications were noted. Thus, FIX-R338L provides an attractive strategy to safely enhance the efficacy of gene therapy for HB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationX-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua)
Simioni, P., Tormene, D., Tognin, G., Gavasso, S., Bulato, C., Iacobelli, N. P., Finn, J. D., Spiezia, L., Radu, C., & Arruda, V. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904377 · Cited by 394
Self-citation
Research works printed but not linked: 16
- Arruda, 2010, Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B., Blood, 115, 4678, 10.1182/blood-2009-12-261156 · DOI · Paper page
- Niemeyer, 2009, Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy., Blood, 113, 797, 10.1182/blood-2008-10-181479 · DOI · Paper page
- High, 2011, Gene therapy for haemophilia: a long and winding road., J Thromb Haemost, 9, 2, 10.1111/j.1538-7836.2011.04369.x · DOI
- Buchlis, 2012, Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer., Blood, 119, 3038, 10.1182/blood-2011-09-382317 · DOI · Paper page
- Jiang, 2006, Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B., Mol Ther, 14, 452, 10.1016/j.ymthe.2006.05.004 · DOI · Paper page
- Schuettrumpf, 2005, Factor IX variants improve gene therapy efficacy for hemophilia B., Blood, 105, 2316, 10.1182/blood-2004-08-2990 · DOI · Paper page
- Brunetti-Pierri, 2009, Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B., Hum Gene Ther, 20, 479, 10.1089/hum.2008.084 · DOI
- Kao, 2010, FIX-Triple, a gain-of-function factor IX variant, improves haemostasis in mouse models without increased risk of thrombosis., Thromb Haemost, 104, 355, 10.1160/TH09-11-0792 · DOI
- Chang, 1998, Changing residue 338 in human factor IX from arginine to alanine causes an increase in catalytic activity., J Biol Chem, 273, 12089, 10.1074/jbc.273.20.12089 · DOI · Paper page
- Haurigot, 2010, Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs., Mol Ther, 18, 1318, 10.1038/mt.2010.73 · DOI · Paper page
- Gregorevic, 2006, rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice., Nat Med, 12, 787, 10.1038/nm1439 · DOI · Paper page
- Arruda, 2005, Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model., Blood, 105, 3458, 10.1182/blood-2004-07-2908 · DOI · Paper page
- Nichols, 2012, Sensitivity of whole blood clotting time and activated partial thromboplastin time for factor IX: relevance to gene therapy and determination of post-transfusion elimination time of canine factor IX in hemophilia B dogs., J Thromb Haemost, 10, 474, 10.1111/j.1538-7836.2011.04613.x · DOI
- Nichols, 2009, Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von Willebrand disease, and factor VII deficiency., ILAR J, 50, 144, 10.1093/ilar.50.2.144 · DOI · Paper page
- Arruda, 2009, Strategies to modulate immune responses: a new frontier for gene therapy., Mol Ther, 17, 1492, 10.1038/mt.2009.150 · DOI · Paper page
- Evans, 1989, Canine hemophilia B resulting from a point mutation with unusual consequences., Proc Natl Acad Sci U S A, 86, 10095, 10.1073/pnas.86.24.10095 · DOI · Paper page
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“Alternatively, high speci fi c-activity transgenes, such as F.IX Padua, 109-111 may allow a reduction in dose to a level that can be tolerated without a need for steroids (vide infra), although the risks of immune responses to variant clotting factor molecules inherent in this approach must be…”
InfluentialSelf-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Multiple studies reduced the therapeutic dose of AAV and utilized hyperactive variants of delivered transgene [88, 193, 230].”
Background
Metadata
- Authors
- Finn, J. D., Nichols, T. C., Svoronos, N., Merricks, E. P., Bellenger, D. A., Zhou, S., Simioni, P., High, K. A., & Arruda, V. R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2012-11-29
- Volume
- 120
- Issue
- 23
- Pages
- 4521-4523
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1998392237
- Cited by
- 110
- References
- 4
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. https://app.cochat.ai/papers/10.1182/blood-2012-06-440123
- The paper
- Finn, J. D., Nichols, T. C., Svoronos, N., Merricks, E. P., Bellenger, D. A., Zhou, S., Simioni, P., High, K. A., & Arruda, V. R. (2012). The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood. https://doi.org/10.1182/blood-2012-06-440123
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.